Table 2.

Improved protease therapies in clinical development

Protease	Developer	Description	Development stage
Desmoteplase	Lundbeck	Recombinant bat t-PA, rDSP	Phase III
FIX–Fc	Biogen Idec	Fusion of an Fc fragment of IgG with FIX	Phase III
FVIIa analogue, NN1731	Novo Nordisk	Fast-acting FVIIaV158D/E296V/M298Q–FVIIa	Phase II
GlycoPEGylated FVIIa, NN7128	Novo Nordisk	Long-acting FVIIa derivative	Phase II
FIX	St. Jude Children’s Research Hospital	Adeno-associated viral vector expressing human FIX (scAAV2/8-LP1-hFIXco)	Phase I/II
GlycoPEGylated FIX, NN7999	Novo Nordisk	Long-acting FIX derivative	Phase I
FIX–albumin fusion	CSL Behring	FIX fused with albumin	Phase I
GlycoPEGylated FVIIa, NN7129	Novo Nordisk	Subcutaneous long-acting FVIIa derivative	Phase I
BAY 86–6150	Bayer Schering Pharma/Maxygen	Recombinant FVIIa variant, developed with gene shuffling technology	Phase I
FIX	Children’s Hospital of Philadelphia	Adeno-associated viral vector expressing human FIX (AAV2-hFIX)	Phase I
FVIIa analogue	Pfizer/Catalyst Biosciences	Engineered FVIIa	Preclinical
PEGylated FIX	Baxter International	Long-acting rFIX derivative	Preclinical
rFVIIa–albumin fusion	CSL Behring	FVIIa fused with albumin	Preclinical
FVIIa–CTP, MOD-5023	Prolor Biotech	Long-acting FVIIa analogue	Preclinical
FXa analogue	Pfizer/Children’s Hospital of Philadelphia	Engineered FXa	Preclinical
Engineered FIX and other proteases	Bayer Schering Pharma/Direvo	Therapase technology, proteases with altered specificity and inhibitor resistance	Preclinical